Phân tích tích hợp hồ sơ mRNA và miRNA cho thấy vai trò của miR-193 và miR-210 như các dấu ấn sinh học điều chỉnh tiềm năng trong các phân nhóm phân tử khác nhau của ung thư vú

IARC. Cancer today. 2019. http://gco.iarc.fr/today/home. Accessed 13 July 2019. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet (London, England). 2011; 378(9805):1812–23. https://doi.org/10.1016/S0140-6736(11)61539-0. Turashvili G, Brogi E. Tumor Heterogeneity in Breast Cancer. Front Med. 2017; 4. https://doi.org/10.3389/fmed.2017.00227. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747–52. https://doi.org/10.1038/35021093. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011; 5(1):5–23. https://doi.org/10.1016/j.molonc.2010.11.003. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61–70. https://doi.org/10.1038/nature11412. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast. 2015; 24:26–35. https://doi.org/10.1016/j.breast.2015.07.008. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF, American Society of Clinical Oncology. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2016; 34(10):1134–50. https://doi.org/10.1200/JCO.2015.65.2289. AJCC. American Joint Committee on Cancer. 2019. https://cancerstaging.org/Pages/default.aspx. Accessed 15 July 2019. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. The Oncologist. 2006; 11(8):868–77. https://doi.org/10.1634/theoncologist.11-8-868. Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol. 2006; 3(11):621–32. https://doi.org/10.1038/ncponc0636. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20(8):460–9. https://doi.org/10.1016/j.molmed.2014.06.005. Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenetics. 2018; 10(1):59. https://doi.org/10.1186/s13148-018-0492-1. Rehman O, Zhuang H, Muhamed Ali A, Ibrahim A, Li Z. Validation of miRNAs as Breast Cancer Biomarkers with a Machine Learning Approach. Cancers. 2019; 11(3). https://doi.org/10.3390/cancers11030431. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281–97. https://doi.org/10.1016/s0092-8674(04)00045-5. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642–55. https://doi.org/10.1016/j.cell.2009.01.035. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci. 2004; 101(9):2999–3004. https://doi.org/10.1073/pnas.0307323101. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009; 60:167–79. https://doi.org/10.1146/annurev.med.59.053006.104707. Stückrath I, Rack B, Janni W, Jäger B, Pantel K, Schwarzenbach H. Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget. 2015; 6(15):13387–401. https://doi.org/10.18632/oncotarget.3874. Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 2016; 7(34):55231–48. https://doi.org/10.18632/oncotarget.10485. Dirks WG, Faehnrich S, Estella IAJ, Drexler HG. Short tandem repeat DNA typing provides an international reference standard for authentication of human cell lines. ALTEX. 2005; 22(2):103–9. Marino ALF, Evangelista AF, Vieira RAC, Macedo T, Kerr LM, Abrahão-Machado LF, Longatto-Filho A, Silveira HCS, Marques MMC. MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study. BMC Cancer. 2014; 14:739. https://doi.org/10.1186/1471-2407-14-739. Evangelista AF, Collares CV, Xavier DJ, Macedo C, Manoel-Caetano FS, Rassi DM, Foss-Freitas MC, Foss MC, Sakamoto-Hojo ET, Nguyen C, Puthier D, Passos GA, Donadi EA. Integrative analysis of the transcriptome profiles observed in type 1, type 2 and gestational diabetes mellitus reveals the role of inflammation. BMC Med Genomics. 2014; 7:28. https://doi.org/10.1186/1755-8794-7-28. Bordinhão ALR, Evangelista AF, Oliveira RJS, Macedo T, Silveira HC, Reis RM, Marques MM. MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib. Oncol Rep. 2016; 36(6):3197–206. https://doi.org/10.3892/or.2016.5153. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2019. http://www.R-project.org/. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke T, Gottardo R, Hahne F, Hansen KD, Irizarry RA, Lawrence M, Love MI, MacDonald J, Obenchain V, Ole’s AK, Pag‘es H, Reyes A, Shannon P, Smyth GK, Tenenbaum D, Waldron L, Morgan M. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015; 12(2):115–21. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):47. https://doi.org/10.1093/nar/gkv007. Pollard KS, Dudoit S, van der Laan MJ. Multiple Testing Procedures: R Multtest Package and Applications to Genomics, in Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York: Springer; 2005. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics. 2006; 22(22):2825–7. https://doi.org/10.1093/bioinformatics/btl476. Tokar T, Pastrello C, Rossos AEM, Abovsky M, Hauschild A-C, Tsay M, Lu R, Jurisica I. mirDIP 4.1-integrative database of human microRNA target predictions. Nucleic Acids Res. 2018; 46(D1):360–70. https://doi.org/10.1093/nar/gkx1144. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 2003; 13(11):2498–504. https://doi.org/10.1101/gr.1239303. Wu G, Dawson E, Duong A, Haw R, Stein L. ReactomeFIViz: a Cytoscape app for pathway and network-based data analysis. F1000Research. 2014; 3. https://doi.org/10.12688/f1000research.4431.2. TCGA. The Cancer Genome Atlas Program. 2018. https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga. Accessed 15 July 2019. Deng M. FirebrowseR: An ’API’ Client for Broads ‘Firehose’ Pipeline. 2016. R package version 1.1.35. https://github.com/mariodeng/FirebrowseR. Kosinski M, Biecek P. RTCGA: The Cancer Genome Atlas Data Integration. 2019. R package version 1.14.0. https://rtcga.github.io/RTCGA. Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res. 2001; 29(9):45. Kammermann M, Denelavas A, Imbach A, Grether U, Dehmlow H, Apfel CM, Hertel C. Impedance measurement: a new method to detect ligand-biased receptor signaling. Biochem Biophys Res Commun. 2011; 412(3):419–24. https://doi.org/10.1016/j.bbrc.2011.07.087. Macedo T, Silva-Oliveira RJ, Silva VAO, Vidal DO, Evangelista AF, Marques MMC. Overexpression of mir-183 and mir-494 promotes proliferation and migration in human breast cancer cell lines. Oncol Lett. 2017; 14(1):1054–60. https://doi.org/10.3892/ol.2017.6265. Silva VAO, Rosa MN, Miranda-Gonçalves V, Costa AM, Tansini A, Evangelista AF, Martinho O, Carloni AC, Jones C, Lima JP, Pianowski LF, Reis RM. Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells. Investig New Drugs. 2019; 37(2):223–37. https://doi.org/10.1007/s10637-018-0620-y. Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, Eliceiri KW. ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics. 2017; 18(1):529. https://doi.org/10.1186/s12859-017-1934-z. Jänicke RU. MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat; 117(1):219–21. https://doi.org/10.1007/s10549-008-0217-9. He Y, Lin J, Kong D, Huang M, Xu C, Kim T-K, Etheridge A, Luo Y, Ding Y, Wang K. Current State of Circulating MicroRNAs as Cancer Biomarkers. Clin Chem. 2015; 61(9):1138–55. https://doi.org/10.1373/clinchem.2015.241190. Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem. 2015; 61(1):56–63. https://doi.org/10.1373/clinchem.2014.221341. Ivan M, Huang X. miR-210: Fine-Tuning the Hypoxic Response. Adv Exp Med Biol. 2014; 772:205–27. https://doi.org/10.1007/978-1-4614-5915-6_10. Gee HE, Ivan C, Calin GA, Ivan M. HypoxamiRs and cancer: from biology to targeted therapy. Antioxid Redox Signal. 2014; 21(8):1220–38. https://doi.org/10.1089/ars.2013.5639. Ding L, Zhao L, Chen W, Liu T, Li Z, Li X. miR-210, a modulator of hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cell. Int J Clin Exp Med. 2015; 8(2):2299–307. Wang W, Qu A, Liu W, Liu Y, Zheng G, Du L, Zhang X, Yang Y, Wang C, Chen X. Circulating miR-210 as a diagnostic and prognostic biomarker for colorectal cancer. Eur J Cancer Care. 2017; 26(4):12448. https://doi.org/10.1111/ecc.12448. Ren D, Yang Q, Dai Y, Guo W, Du H, Song L, Peng X. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-kB signaling pathway. Mol Cancer. 2017; 16(1):117. https://doi.org/10.1186/s12943-017-0688-6. Świtlik W, Karbownik MS, Suwalski M, Kozak J, Szemraj J. miR-30a-5p together with miR-210-3p as a promising biomarker for non-small cell lung cancer: A preliminary study. Cancer Biomark Sect A Dis Markers. 2018; 21(2):479–88. https://doi.org/10.3233/CBM-170767. Dang K, Myers KA. The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci. 2015; 16(3):6353–72. https://doi.org/10.3390/ijms16036353. Ono S, Oyama T, Lam S, Chong K, Foshag LJ, Hoon DSB. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget. 2015; 6(9):7053–64. https://doi.org/10.18632/oncotarget.3142. Huang X, Zuo J. Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response. Acta Biochim Biophys Sin. 2014; 46(3):220–32. https://doi.org/10.1093/abbs/gmt141. Adhami M, Haghdoost AA, Sadeghi B, Malekpour Afshar R. Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer. 2018; 25(2):198–205. https://doi.org/10.1007/s12282-017-0814-8. Shi Y, Ye P, Long X. Differential Expression Profiles of the Transcriptome in Breast Cancer Cell Lines Revealed by Next Generation Sequencing. Cell Physiol Biochem. 2017; 44(2):804–16. https://doi.org/10.1159/000485344. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011; 10(3):507–17. https://doi.org/10.4161/cc.10.3.14754. Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, Takahashi S, Fujii Y, Yamashita H. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol. 2012; 42(4):256–63. https://doi.org/10.1093/jjco/hys001. Wang J, Zhao J, Shi M, Ding Y, Sun H, Yuan F, Zou Z. Elevated expression of miR-210 predicts poor survival of cancer patients: a systematic review and meta-analysis. PloS ONE. 2014; 9(2):89223. https://doi.org/10.1371/journal.pone.0089223. Zheng Z, Liu L, Zhan Y, Yu S, Kang T. Adipose-derived stem cell-derived microvesicle-released miR-210 promoted proliferation, migration and invasion of endothelial cells by regulating RUNX3. Cell Cycle (Georgetown Tex). 2018; 17(8):1026–33. https://doi.org/10.1080/15384101.2018.1480207. Jiang Y, Tong D, Lou G, Zhang Y, Geng J. Expression of RUNX3 Gene, Methylation Status and Clinicopathological Significance in Breast Cancer and Breast Cancer Cell Lines. Pathobiology. 2008; 75(4):244–51. https://doi.org/10.1159/000132385. Chen L-F. Tumor suppressor function of RUNX3 in breast cancer. J Cell Biochem. 2012; 113(5):1470–7. https://doi.org/10.1002/jcb.24074. Bai X, Han G, Liu Y, Jiang H, He Q. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3. BioMed Pharmacother Biomedecine Pharmacotherapie. 2018; 103:1482–9. https://doi.org/10.1016/j.biopha.2018.04.165. Khordadmehr M, Shahbazi R, Sadreddini S, Baradaran B. miR-193: A new weapon against cancer. J Cell Physiol. 2019; 234(10):16861–72. https://doi.org/10.1002/jcp.28368. Jian B, Li Z, Xiao D, He G, Bai L, Yang Q. Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016; 37(7):8941–9. https://doi.org/10.1007/s13277-015-4727-x. Liu L, Li Y, Liu S, Duan Q, Chen L, Wu T, Qian H, Yang S, Xin D. Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017; 39(6):1010428317711951. https://doi.org/10.1177/1010428317711951. Liang H, Liu M, Yan X, Zhou Y, Wang W, Wang X, Fu Z, Wang N, Zhang S, Wang Y, Zen K, Zhang C-Y, Hou D, Li J, Chen X. miR-193a-3p Functions as a Tumor Suppressor in Lung Cancer by Down-regulating ERBB4. J Biol Chem. 2015; 290(2):926–40. https://doi.org/10.1074/jbc.M114.621409. Leivonen S-K, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellström K, Sahlberg N, Kristensen VN, Børresen-Dale A. -L., Saviranta P, Perälä M, Kallioniemi O. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 2009; 28(44):3926–36. https://doi.org/10.1038/onc.2009.241. Hulin J-A, Tommasi S, Elliot D, Hu DG, Lewis BC, Mangoni AA. MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1. Sci Rep. 2017; 7. https://doi.org/10.1038/s41598-017-14454-1. Chen J, Feilotter HE, Paré GC, Zhang X, Pemberton JGW, Garady C, Lai D, Yang X, Tron VA. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol. 2010; 176(5):2520–9. https://doi.org/10.2353/ajpath.2010.091061. Nakano H, Yamada Y, Miyazawa T, Yoshida T. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol. 2013; 42(6):1875–82. https://doi.org/10.3892/ijo.2013.1896. Kaukoniemi KM, Rauhala HE, Scaravilli M, Latonen L, Annala M, Vessella RL, Nykter M, Tammela TLJ, Visakorpi T. Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. Cancer Med. 2015; 4(9):1417–25. https://doi.org/10.1002/cam4.486. Tsai K-W, Leung C-M, Lo Y-H, Chen T-W, Chan W-C, Yu S-Y, Tu Y-T, Lam H-C, Li S-C, Ger L-P, Liu W-S, Chang H-T. Arm Selection Preference of MicroRNA-193a Varies in Breast Cancer. Scientific Reports. 2016; 6. https://doi.org/10.1038/srep28176. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003; 22(53):8628–33. https://doi.org/10.1038/sj.onc.1207232. von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 2017; 17(6):352–66. https://doi.org/10.1038/nrc.2017.28. Labovsky V, Martinez LM, Davies KM, de Luján Calcagno M, García-Rivello H, Wernicke A, Feldman L, Matas A, Giorello MB, Borzone FR, Choi H, Howard SC, Chasseing NA. Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer. BMC Cancer. 2017; 17(1):280. https://doi.org/10.1186/s12885-017-3259-8. Heilmann T, Vondung F, Borzikowsky C, Szymczak S, Krüger S, Alkatout I, Wenners A, Bauer M, Klapper W, Röcken C, Maass N, von Karstedt S, Schem C, Trauzold A. Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. J Mol Med (Berlin, Germany). 2019; 97(8):1155–67. https://doi.org/10.1007/s00109-019-01805-w. Ng EKO, Li R, Shin VY, Siu JM, Ma ESK, Kwong A. MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014; 35(3):2591–8. https://doi.org/10.1007/s13277-013-1341-7. Venza M, Visalli M, Catalano T, Fortunato C, Oteri R, Teti D, Venza I. Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma. Biochem Biophys Res Commun. 2013; 441(4):743–50. https://doi.org/10.1016/j.bbrc.2013.10.114.